These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1253 related articles for article (PubMed ID: 28532651)

  • 21. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
    Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
    Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
    Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in Prevalence of Non-Valvular Atrial Fibrillation and Anticoagulation Therapy in a Japanese Region　- Analysis Using the National Health Insurance Database.
    Narita N; Okumura K; Kinjo T; Mikami J; Tsushima K; Takahashi R; Noro M; Hashimoto A; Sasaki T; Takaki M; Ishidoya E; Narita Y; Imai H; Ono E; Tomita H
    Circ J; 2020 Apr; 84(5):706-713. PubMed ID: 32213724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prothrombin time on admission in patients with cardioembolic stroke and intracranial hemorrhage occurring during warfarin treatment in the direct oral anticoagulant era].
    Okumura K; Hagii J; Metoki N; Saito S; Shiroto H; Yasujima M; Tomita H
    Rinsho Shinkeigaku; 2016 May; 56(5):309-17. PubMed ID: 27151227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
    Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.
    Goto S; Goto S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Haas S; Parkhomenko A; Oto A; Misselwitz F; Turpie AGG; Verheugt FWA; Fox KAA; Gersh BJ; Kakkar AK
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):301-309. PubMed ID: 31821482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation.
    Deguchi I; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2627-2631. PubMed ID: 29970321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
    Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
    Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.
    Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):205-11. PubMed ID: 25944648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
    Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
    J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.
    Tagaya M; Yoshikawa D; Sugishita Y; Yamauchi F; Ito T; Kamada T; Yoshinaga M; Mukaide D; Fujiwara W; Yokoi H; Hayashi M; Watanabe E; Ishii J; Ozaki Y; Izawa H
    Heart Vessels; 2016 Jun; 31(6):957-62. PubMed ID: 26022376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
    Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
    Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use.
    Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005894. PubMed ID: 32160790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.
    Chopard R; Piazza G; Hurwitz S; Fanikos J; Goldhaber SZ
    J Thromb Thrombolysis; 2019 Feb; 47(2):331-335. PubMed ID: 30449000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations.
    Stacy ZA; Richter SK
    Ther Adv Cardiovasc Dis; 2018 Sep; 12(9):247-262. PubMed ID: 30081727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis.
    Yamashita T; Inoue H; Okumura K; Atarashi H; Origasa H;
    J Cardiol; 2015 Mar; 65(3):175-7. PubMed ID: 25169015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.